

PUBLISHED VERSION

Antonina Mikocka-Walus, Patrick A. Hughes, Peter Bampton, Andrea Gordon, Melissa A. Campaniello, Chris Mavrangelos, Benjamin J. Stewart, Adrian Esterman, Jane M. Andrews
Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn's disease: a pilot randomised placebo-controlled trial
Journal of Crohn's & colitis, 2017; 11(4):509-514

© European Crohn's and Colitis Organisation (ECCO) 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Originally published at:
<http://doi.org/10.1093/ecco-jcc/jjw165>

PERMISSIONS

<http://creativecommons.org/licenses/by-nc/4.0/>



Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

This is a human-readable summary of (and not a substitute for) the [license](#). [Disclaimer](#).

You are free to:

- Share** — copy and redistribute the material in any medium or format
- Adapt** — remix, transform, and build upon the material

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:



Attribution — You must give [appropriate credit](#), provide a link to the license, and [indicate if changes were made](#). You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.



NonCommercial — You may not use the material for [commercial purposes](#).

No additional restrictions — You may not apply legal terms or [technological measures](#) that legally restrict others from doing anything the license permits.

31 July 2017

<http://hdl.handle.net/2440/105164>